Wernicke\u27s Encephalopathy by Radu Tanasescu et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Radu Tanasescu1,2 et al.* 
1Carol Davila University of Medicine and Pharmacy, Bucharest,  
2Department of Neurology, Colentina Clinical Hospital, Bucharest  
Romania 
1. Introduction 
Wernicke’s Encephalopathy (WE) is an underdiagnosed, potentially fatal, acute or subacute 
neurologic disorder caused by the impairment of thiamine (vitamin B1) -dependent 
enzymatic activity in susceptible brain cells. The biologically active form of thiamine (TH), 
thiamine diphosphate (THDP), serves as a cofactor for several apoenzymes involved mainly 
in the carbohydrate metabolism. Except for very rare cases, WE occurs in the presence of TH 
deficiency, which is directly related to at least two other clinical entities: neurological 
beriberi and cardiovascular beriberi. The preferential expression of one (or more) of these 
entities may be the consequence of genetic polymorphism of genes encoding TH 
transporters. The topography of WE brain lesions is highly specific, typically the 
periventricular and periaqueductal grey areas being symmetrically involved. In the majority 
of cases the early so-called ‘biochemical lesions’ are completely reversed if TH is promptly 
supplied. However, if the THDP dependent enzymatic activity is not restored, irreversible 
structural damage and eventually exitus may occur (Donnino, Vega et al. 2007; Hazell and 
Butterworth 2009; Thorarinsson, Olafsson et al. 2011). 
Carl Wernicke was the first to describe the clinical and neuropathological characteristics of 
the encephalopathy that currently, according to the ICD-10 (WHO 2010), bears his name. 
The first case compatible with WE was reported in 1822 by James Jackson. In the following 
years Samuel Wilks (1868) and Charles Gayet (1875) encountered other similar cases. In 
1881, Carl Wernicke published the cases of three patients - two alcohol abusing men, and a 
young woman with persistent vomiting - that died within two weeks after the acute onset of 
the nowadays considered classical triad – i.e. stance and/or gait ataxia, ocular motility sings 
and mental-status changes - accompanied by similar fundoscopic modifications. 
Neuropathological examinations were conducted. Wernicke considered that they all had the 
same disease he named ‘polioencephalitis haemorrhagica superioris’ (Pearce 2008; 
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Thorarinsson, Olafsson et al. 2011). During the late 1880’s, Korsakoff published three 
comprehensive series of cases presenting the characteristic features of the amnestic 
syndrome that currently bears his name (i.e. Korsakoff syndrome/’psychosis’, KS), 
commonly preceded or accompanied by a clinical picture highly suggestive of WE. He 
considered that all these patients had the same disease he named ‘polyneuritic psychosis’. 
The KS results from the bilateral dysfunction of the limbic system. As expected considering 
the distribution of WE lesions, KS frequently accompanies WE. The association between WE 
and KS was noticed and in this respect acute or sequelar WE with prominent KS and/or 
post-WE KS are denominated by some Wernicke-Korsakoff syndrome (WKS). The etiology 
and treatment of WE remained unknown until up to almost the half of the XXth century. 
Beginning with Strauss (1935), Campbell (1940), Russell (1940) and Phillips (1952), who 
established that TH deficiency is directly related to the development of WE, and with 
Williams and Cline (1936), who published the first correct TH chemical formula and 
synthesis pathway, remarkable progress has been made in understanding the spectrum of 
diseases caused by TH deficiency (Phillips, Victor et al. 1952; Donnino, Vega et al. 2007). 
Currently, WE is a highly and easily treatable disease frequently associated with alcoholism 
and/or malnutrition related TH deficiency. The diagnosis remains mainly clinical as none of 
the modern diagnostic tools has adequate sensitivity and/or specificity. The classical triad is 
encountered in less than a third of cases and may be completely absent. The clinical picture 
may vary from the classical signs to hypotension or coma. Unfortunately, the misconception 
that WE is a rare and stereotypic disease occurring only in malnourished alcoholics is still 
found in clinical practice, frequently leading to the delay or even failure of diagnosis 
(Tanasescu 2009). 
The following chapter provides a thorough overview of WE, with updates on the recent 
epidemiological and etiophysiopathological data. A brief reference to the possibility of 
effective prophylaxis is made. The diagnosis and treatment are discussed. The relationship 
with other TH deficiency diseases, the particularities of alcohol versus non-alcohol related 
cases and the correlations with KS are underlined. Considering the deleterious 
consequences of untreated WE, the importance of maintaining a high index of suspicion for 
diagnosis and a low threshold for parenteral TH administration - as recommended by the 
2010 EFNS guideline - is advocated (Galvin, Brathen et al. 2010). 
2. Epidemiology 
WE epidemiological data are scarce and mostly based on necroptic class IV studies 
conducted in the developed countries. However the literature is abundant in case reports 
and to a lesser extent in small retrospective clinical studies. WE occurs throughout the 
world, but, even if considering the probable report bias, appears to have uneven geographic 
distribution (Galvin, Brathen et al. 2010).  
According to the retrospective clinical studies available, the prevalence of WE is lower than 
0.13%. Nevertheless, necropsies of the general population reveal brain lesions consistent 
with WE in 0.4 to 2.8% of the cases (average 1.3%), the highest rates being reported in West 
Australia during the 1970’s (Harper 1979; Harper 1983; Harper, Giles et al. 1986). In prior 
alcohol abusers the prevalence of neuropathology confirmed WE is reported to be around 






with alcohol related deaths, WE prevalence may reach 59% (Victor, Adams et al. 1971; 
Thomson and Marshall 2006). Other populations with significantly higher WE prevalence 
were identified, necroptic changes compatible with WE being found in approximately 10% 
of the AIDS patients and in 6% of those that underwent bone marrow transplant 
(Butterworth, Gaudreau et al. 1991; Boldorini, Vago et al. 1992; Donnino, Vega et al. 2007). 
The correct diagnosis of WE is made prior to necropsy in only up to 25% of the adult cases 
(values as low as 1% being reported!), and in approximately 40% of the pediatric cases). Up 
to 70% of the alcohol related cases and almost 95% of the non alcohol related cases are not 
diagnosed prior to death (Victor, Adams et al. 1971; Harper, Giles et al. 1986; Harper, Gold 
et al. 1989; Torvik 1991; Vasconcelos, Silva et al. 1999). AIDS patients seem to be the category 
most often misdiagnosed (Butterworth, Gaudreau et al. 1991). Considering the discrepancy 
between the prevalence of the clinic versus necroptic diagnosis (0.4-2.8% versus 0.04-0.13%), 
WE appears to be underdiagnosed during lifetime (Victor, Adams et al. 1971). Since 
necropsy studies may be biased towards preferentially identifying the more severe cases, 
the prevalence of WE may be even higher than the one predicted by the necroptic studies 
(Galvin, Brathen et al. 2010). However, some have suggested that the histopathological 
changes may precede the clinical onset of disease, and thus the necropsies of the general 
population may also identify mild subclinical cases (Caine, Halliday et al. 1997). It was 
estimated that 13 to 35% of alcoholics and up to 1.5% of the non-alcoholics develop WE 
(Harper, Rodriguez et al. 1988). The incidence and prevalence of WE are considered to be at 
least 10 times higher in alcoholics than in non-alcoholics (Harper 2006). In order to have a 
clearer picture, the 2010 EFNS guideline recommends performing necropsies with detailed 
neuropathological examination in all patients dying from diseases suggestive of WE 
(Galvin, Brathen et al. 2010). 
Besides exceptionally rare cases, all WE patients have TH deficiency. According to the 
available data, TH deficiency is not uncommon in the developed countries. In the UK, 
approximately 20% of the patients admitted to the emergency departments had TH 
deficiency (Jamieson, Obeid et al. 1999). In the USA, 8 to 31% of the elderly living at home 
and 23 to 40% of those in nursing homes had TH deficiency (Harper 2006). In Canada, TH 
deficiency was found in almost 13% of the critically ill children (Fattal-Valevski 2011). 
During the 1992-1993 Cuban neuropathy epidemic the local prevalence of TH deficiency 
ranged from 30% in some regions to 70% in others (Macias-Matos, Rodriguez-Ojea et al. 
1996). Among chronic alcoholics, 25 to 80% may have a certain degree of TH deficiency 
(Caine, Halliday et al. 1997). Several studies on AIDS patients found TH deficiency in 10 to 
23% of the cases (Davtyan and Vinters 1987; Foresti and Confalonieri 1987; Hutchin 1987). 
According to the WHO’s report on TH (WHO 1999), in South-East Asia TH deficiency has a 
high prevalence, while in Africa and Central and North America it has a low prevalence. 
Chronic ethanol consumption and/or malnutrition have a significant impact on the 
incidence and prevalence of WE, up to 90% of the WE patients having TH deficiency in this 
context (Antunez, Estruch et al. 1998). Several important TH deficiency epidemics have been 
recorded by the modern history. At the beginning of the XXth century the introduction of 
the large scale use of cheap polished rice in urban South-East Asia led to several great 
outbreaks of TH deficiency associated with beriberi. During the last two decades of the XXth 
century TH deficiency epidemics were recorded in Thailand, Guinea, Djibouti, East Ethiopia 
and Nepal, especially among political refugees (WHO 1999). In 2003 a TH deficiency 
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outbreak affecting infants fed with a soy milk formula with no detectible TH content 
emerged in Israel (Fattal-Valevski, Kesler et al. 2005). To the best of our knowledge, WE-
related epidemiologic data from the developing or underdeveloped countries are not 
available. Approximately 90% of the WE cases occurring in the developed countries are 
alcohol related (Thomson 2000). A correlation between the per capita alcohol consumption 
and the prevalence of WE could not be established (Torvik 1991). The male to female ratios 
range from 1.7:1 to 3:1 in necroptic studies, and were reported to be 5:1 in a large clinical 
study (Victor, Adams et al. 1971; Harper 1979; Victor 1989; Rolland and Truswell 1998). WE 
may affect individuals of any age but appears to have a higher prevalence during the fifth 
decade of life (Vasconcelos, Silva et al. 1999). A trend towards an increased incidence and 
prevalence of WE has recently been observed in USA, UK and Japan, possibly related to the 
increased number of bariatric surgery interventions and the persistent shortages in 
intravenous vitamins, to the restriction of parenteral TH administration due to fear of 
anaphylaxis (leading to the routine prophylaxis in hospitalized alcoholics with per os 
instead of parenteral thiamine) and respectively to the restriction of parenteral vitamins 
supplementation by a healthcare policy (Ramayya and Jauhar 1997; Hahn, Berquist et al. 
1998; Shikata, Mizutani et al. 2000; Feeney and Connor 2008). Several regional socio-
economic and cultural particularities along with local health care related factors appear to 
have important influences on the prevalence and prognosis of WE.  Considering the 
important burden that untreated WE puts on health care systems worldwide (Galvin, 
Brathen et al. 2010), further epidemiological studies are needed in order to better define the 
populations at risk and to identify efficient prophylactic approaches. 
3. Etiology 
WE is caused by the disruption of the THDP dependent enzymatic activity in susceptible 
brain cells, commonly secondary to TH deficiency. This correlates directly with three 
pathogenic entities: WE, cardiovascular beriberi, and neuropathic beriberi. Recently, two 
other conditions that seem to be directly related to TH deficiency have been described: 
African (Nigerian) seasonal ataxia and gastrointestinal beriberi (Adamolekun and Ndububa 
1994; Nishimune, Watanabe et al. 2000; Donnino 2004). TH deficiency seems also to be 
involved in other diseases like Strachan syndrome (i.e. polyneuropathy, optic neuropathy, 
orogenital ulcerations), ‘tobacco-alcohol amblyopia’, tropical ataxic neuropathy (i.e. sensory 
neuropathy, optic neuropathy, sensoneural deafness), Marchiafava-Bignami disease, 
subacute ‘alcoholic’ cerebellar degeneration and epidemic spastic paraparesis (konzo). TH 
competitive antagonists and/or impaired TH to THDP conversion may lead to WE even in 
the presence of normal TH blood levels. Impaired apoenzyme activation due to magnesium 
(Mg) deficiency, and/or decreased activity of the THDP dependent enzymes may condition 
the degree of susceptibility to borderline low levels of THDP. Due to physiologic 
particularities not all tissues are equally susceptible, the nervous system and the cardiac 
muscle being the most vulnerable. The pattern of cellular susceptibility may be influenced 
by genetic and environmental factors, including the nutritional and hormonal status, and 
seems not to be homogenously represented among individuals, thus possibly explaining the 
preferential expression of one (or more) of the potential pathologic entities related to TH 







TH is a water soluble heat labile quaternary ammonia compound, containing an 
aminopyrimidine ring linked by a methylene bridge to a thiazole ring. It is synthesized by 
different biochemical reactions in fungi, bacteria, plants and some protozoa, but not in 
humans (Fattal-Valevski 2011). In the human body it is found as unphosporilated TH (i.e. 
free TH) and as phosphorilated derivates: TH monophospate (THMP), TH diphospate 
(THDP, aka TH pyrophosphate), and TH triphospate (THTP). Intracellularly, free TH is 
converted by thiaminpyrophosphokinase into THDP, in a process requiring Mg as cofactor. 
Three plasma membrane bidirectional transporters for TH and TH derivates have been 
described: TH transporter 1 (THTR1) encoded by the SCL19A2 gene (location 1q23.3), TH 
transporter 2 (THTR2) encoded by the SCL19A3 gene (location 2q37) and reduced folate 
carrier transporter 1 (RFC1) encoded by the SCL19A1 gene (location 21q22.3). A 
mitochondria membrane transporter for THDP (i.e. mitochondria membrane THDP 
transporter) encoded by the SCL25A19 has also been described. THTR1 and THTR2 
transport free TH. THTR1 seems to be highly expressed in skeletal and heart muscle and to 
lesser degrees in placenta, liver, kidneys, small intestine and lungs. THTR2 seems to be 
highly express in the placenta, kidneys, liver and thalamus and also in the small intestine. 
RFC1 is mainly a folate transporter, but also transports THDP and THMP. Considering that 
THDP is found exclusively intracellularly, RFC1 transports THDP only from the 
intracellular to the extracellular space (where THDP is rapidly converted to free TH). In the 
presence of low free TH and THMP plasma levels the cells that highly express RFC1 on their 
membranes have an overall negative TH balance, exporting THDP without importing free 
TH or THMP. RFC1 is highly expressed on the apical brush border of the choroid plexus. 
The pattern of distribution of the TH and TH derivates transporters may play a significant 
role in establishing and maintaining the tissue distribution of TH (Boulware, Subramanian 
et al. 2003; Subramanian, Marchant et al. 2003; Said, Balamurugan et al. 2004; Miyajima and 
Kono 2010). The intestinal absorption of TH occurs mainly in the proximal small intestine by 
an active saturable mechanism and probably also by passive diffusion. At the intestinal 
brush border TH is mainly found in its free form. TH absorption is enhanced by TH 
deficiency and reduced by thyroid hormones, ethanol exposure, low temperature and TH 
analogs. TH absorption may also be reduced in those with diabetes mellitus or advanced 
aged. At low concentration (<2 microM/liter) TH absorption is an active, rate-limited 
process, involving the high affinity THTR2 and, to a lesser extent, THTR1. At high intestinal 
TH concentration (5-50 microM/liter) TH seems to be absorbed through passive diffusion. It 
has been reported that under physiological circumstances, even when large TH quantities 
are administered, no more than 4.5 to 5 mg can be absorbed from a single oral dose. TH has 
restricted distribution. Up to 90% of the circulating TH is found in the red cells (mostly as 
THDP), the rest being found in the other blood cells and in plasma, mainly bound by 
proteins, as free TH or THMP (Dudeja, Tyagi et al. 2001; Martin, Singleton et al. 2003). 
Under physiologic circumstances, TH is excreted renally. In the presence of high plasmatic 
TH concentration rapid renal excretion as free TH occurs. After the intravenous 
administration of 50 mg of TH hydrochloride the plasma half-time is about 96 minutes. 
Thus, for correcting TH deficiency the administration of parenteral TH in many smaller 
doses rather than in an equivalent single dose seems justified (Donnino; Boulware, 
Subramanian et al. 2003). The blood brain barrier (BBB) allows the passage of free TH and 
THMP through both active and passive mechanisms. Active passage occurs at low TH 
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serum concentrations. At high serum concentrations, free TH passes the BBB passively, 
driven by the existing concentration gradient. The intravenous administration of TH 
provides a superior concentration gradient that facilitates passive diffusion (Thomson, Cook 
et al. 2002). Several natural and synthetic TH structural analogues having different 
pharmacological profiles exist. Pyrithiamine and oxythiamine act as competitive 
antagonists. Pyrithiamine passes the BBB and thus is useful for inducing TH deficiency 
encephalopathy, the experimental model of WE. TH hydrochloride and TH mononitrate are 
water soluble TH salts that act as TH agonists and have similar bioavailability, distribution 
and excretion with TH. Allithiamine is a naturally occurring lipophylic TH analogue 
resulting from the enzymatic conversion of TH in the freshly crushed bulbs of garlic and 
other alli plants. Thiaminetetrahydrofufuryl disulfide is a synthetic analogue of allithiamine. 
Prosultiamine and sulbutiamine are lipid-soluble synthetic TH analogues. All these 
lipophylic TH derivates have better bioavailability and BBB penetrability than TH. 
Benfotiamine is a synthetic TH analogue that has better bioavailability and cellular 
penetrability than TH, but does not pass the BBB (Baker and Frank 1976; Kitamori and 
Itokawa 1993). TH may have a structural role as part of the cellular membranes, and may be 
involved in the synaptic transmission, cellular differentiation, axonal growth, 
myelinogenesis and regulation of brain development during fetal and early postnatal life. To 
the best of our knowledge THMP and THTP have no clearly identified metabolic or 
structural roles (Makarchikov, Lakaye et al. 2003). THDP serves as a cofactor for several 
apoenzymes involved in the carbohydrate metabolism: apo-alpha-ketoglutarate 
dehydrogenase (aKGDH), apo-pyruvate dehydrogenase (PDH) and apo-transketolase (TK). 
Mg is the second cofactor required by these apoenzymes, especially by apo-TK. aKGDH and 
PDH are mitochondrial enzymes important for the tricarboxylic acid cycle (TAC, i.e. Krebs 
cycle), though the latter is not part of it. TK is a cytosolic enzyme involved in the non-
oxidative phase of the pentose-phosphate pathway (PPP or hexose monophosphat shunt). It 
has been shown that TH deficiency inhibits the expression of the genes encoding TK and 
PDH (Pekovich, Martin et al. 1998; Donnino, Vega et al. 2007). Under physiologic 
circumstances, almost 30% of the brain glucose is metabolized to pyruvate. In the absence of 
a functional PDH complex and Krebs cycle pyruvate is reduced to lactate (Ishii, Sarai et al. 
1979). The human body has TH deposits ranging from 25 to 50 mg, commonly 
corresponding to the amount of TH required for 18 to 42 days. Most of the TH is stored in 
the liver as THDP. Food sources of TH are cereals, beans, nuts, brown (unpolished) rice and 
meat. Polished (white) rice, highly purified cereals and excessively cooked food may contain 
no TH. The daily TH requirements for a healthy adult may range from 1 to 2 mg and 
depend on the carbohydrate intake and on several metabolic factors. According to the 
current literature, the TH intake should be of at least 0.33 mg per 1000 kcal, ideally 0.5 mg 
per 1000 kcal, but no less than 1 mg per day. Some recommend daily intakes above 1.1 mg 
for adult women and 1.2 mg for adult men, even if the corresponding caloric intake is lower. 
A balanced diet usually contains the recommended quantity. No upper tolerability limit 
intake has been established for TH and to the best of our knowledge no cases of oral TH 
toxicity have been described (WHO 1999; Thomson and Marshall 2006; Sechi and Serra 2007; 
Fattal-Valevski 2011).  
The TH content of pharmacological or biological samples may be measured directly by 
several methods including spectrophotometry, spectrofluorometry, various techniques of 






The classical method used to assess the human THDP status is the estimation of the effect of 
THDP on the erythrocyte TK activity (ETKA). A low ETKA with more than 25% increase 
after THDP adding confirms THDP erythrocyte deficit, and though indirect, has good 
sensibility, specificity and reproducibility in estimating the whole blood total TH and the 
erythrocyte THDP levels. However, since it is laborious, it has been replaced by the direct 
measurement of the total TH (free TH and its phosphatesters) or of THDP in the whole 
blood using various techniques of HPLC. The whole blood THDP levels correlate well with 
erythrocyte THDP levels providing the correction with the haemoglobin level is made. The 
measurement of whole blood THDP was suggested to be the most suitable method for use 
in clinical practice. (Lee, Ong et al. 1991; Tallaksen, Bell et al. 1993; Herve, Beyne et al. 1994). 
In the apparently healthy human adults the THDP and total TH blood levels range within 
nanomoles per liter levels, specific values depending upon the technique used. In animal 
studies the lethal blood TH level ranges from 7.2 to 10 mg/dl. Death occurs due to 
respiratory failure. If respiratory support is provided blood levels as high as 36.9 mg/dl are 
tolerated (Smith, Foa et al. 1947; Galvin, Brathen et al. 2010). 
3.2 Predisposing factors 
TH deficiency is the predisposing factor most frequently associated with WE. TH deficiency 
is the consequence of one or more of the following mechanisms: inadequate dietary intake 
(absolute or relative), impaired intestinal absorption, impaired storage, excessive 
elimination and/or increased metabolic requirements. Impaired TH intestinal absorption 
may occur due to gastrointestinal diseases, protein-caloric malnutrition (decrease in the 
active TH absorption) and/or ingestion of certain substances (e.g. ‘anti-TH factors’, antacids, 
phenytoin, cephalosporins, tetracycline). Impaired TH storage may occur due to chronic 
liver disease. Excessive renal elimination may occur due to renal disease, use of certain 
drugs and/or impaired TH storage. In those already marginally deficient WE may be 
precipitated by an event that rapidly increases the metabolic requirements of TH. In most of 
the cases, TH deficiency may be traced back to improper diet. Regardless of the cause, 
unbalanced nutrition persisting for more than 14 to 21 days, or even less in those already 
marginally deficient or with higher demands, may lead to TH deficiency. In healthy adults, 
intakes of less than 0.2 mg per 1000 kcal or of less than 0.66 mg per day lasting for several 
weeks lead to clinically manifest TH deficiency. Diets rich in the so-called ‘anti-TH factors’ 
(i.e. ‘thiaminases’ and dietary ‘TH antagonists’) may result in TH deficiency. The 
thiaminases are heat labile enzymes that disintegrate TH (found in raw or fermented fish, 
shellfish, ferns and certain bacteria) or reduce its intrinsic activity (found in certain bacteria). 
The dietary ‘TH antagonists’ are heat stable non-enzymatic substances that interfere with 
the intestinal absorption of TH, including polyphenols (e.g. caffeic acid, chlorogenic acid, 
tannic acid, tartaric acid, citric acid, ascorbic acid which are found in tea, coffee, betel nuts, 
red currants), flavonoids (quercetin and rutin, found mainly in fruits), haemin (found in 
animal tissues) and sulphites in high amounts (WHO 1999; Thomson and Marshall 2006; 
Fattal-Valevski 2011). Gender may influence the risk of developing WE, possibly because of 
genetic differences but also because of gender-related environmental factors. No definite 
race predisposition has been described, but a population-specific susceptibility has been 
reported: it seems that Asians with TH deficiency are prone to cardiovascular beriberi, while 
Europeans with TH deficiency are more likely develop neurological beriberi and/or WE 
(Sechi and Serra 2007).  
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Chronic ethanol abuse is the condition most frequently associated to WE. Alcoholics may 
have higher TH demands, TH being necessary for the metabolism of ethanol. They 
frequently have TH intake below 0.29 mg per 1000 kcal and associate Mg depletion 
(Thomson 2000). They may have impaired TH absorption secondary to ethanol-induced 
intestinal mucosa damage, impaired transmembrane transport due to folate or other B 
vitamins deficiency, decreased intestinal ATP-ase activity and reduced expression of the 
THTR1 and THTR2 encoding genes (Hoyumpa 1980; Subramanya, Subramanian et al. 2010). 
The type of alcoholic beverage consumed may have an influence (Lemos, Azevedo et al. 
2005). TH malabsorption seems to be reversible providing ethanol consumption stops 
(Bujanda 2000). Considering that not all alcoholics with similar nutritional status develop 
WE, it may be speculated that other environmental and/or genetic factors may interfere 
(Mukherjee, Svoronos et al. 1987). Physiological hypercatabolic states like infancy, 
pregnancy and lactation may predispose to TH deficiency. A particular situation is that of 
hyperemesis gravidarium. It has been reported that vomiting persisting for more than three 
weeks and elevated transaminase levels highly correlate with the occurrence of WE in 
pregnant women (Rotman, Hassin et al. 1994 ). The infants fed by TH deficient mother or by 
TH deficient milk formula develop TH deficiency. Pathological hypercatabolic states may 
predispose to TH deficiency not only because of increase TH requirements but also because 
they are frequently associated with improper nutrition, impaired intestinal absorption, 
persistent vomiting and use of drugs that may interfere with TH utilization (Otsuka, Tada et 
al. 1997; Sechi and Serra 2007). In children, malignancy has been reported to be the condition 
most frequently associated to WE (Vasconcelos, Silva et al. 1999). Gastrointestinal surgery 
that removes or by-passes the parts of the gastrointestinal system involved in TH absorption 
is an important predisposing factor for TH deficiency. Bariatric surgery has been identified 
as predisposing factor in a significant number of the recently reported WE cases. Persistent 
vomiting may lead to TH deficiency if adequate parenteral supplementation is not provided 
(Singh and Kumar 2007). Chronic liver disease (occurring in up to half of the alcoholics 
developing WE) may lead to TH deficiency due to impaired storage. Hemodialysis and 
peritoneal dialysis have been reported to increase TH elimination (Sun, Yang et al. 2006; 
Ueda, Utsunomiya et al. 2007). Uremic encephalopathy may cause impaired cerebral TK 
activity and thus may predispose to WE (Brouns and De Deyn 2004). High doses of 
intravenous glucose may precipitate WE in marginally TH deficient individuals. Refeeding, 
hyperalimentation and total parenteral nutrition without adequate TH supplementation 
may also precipitate iatrogenic WE (Watson, Walker et al. 1981). Drugs such as nitroglycerin 
and tolazamide may may play a role in the development of WE in susceptible individuals 
(Sechi and Serra 2007). The chronic use of metronidazole may predispose to WE due to its 
conversion into a TH analogue that acts as a TH competitive antagonist (Alston and Abeles 
1987). The chemotherapeutic drugs 5-fluorouracil, cisplatin, erbulozole and ifosfamide seem 
to interfere with TH pharmacokinetics, predisposing to WE (Van Belle, Distelmans et al. 
1993; Kondo, Fujiwara et al. 1996; Hamadani and Awan 2006; Cho, Chang et al. 2009). WE 
occurring during the chronic use of tolazamide, a sulfonylurea blood glucose lowering drug 
that might increase the intracellular demands of TH, has been reported (Kwee and Nakada 
1983).  
Several genetic factors seem to predispose to the development of WE. The occurrence of WE 
is more frequently encountered in both monozygotic twins than in both heterozygote twins 






aggregation has been reported. The function and/or upregulation of the receptors 
responsible for the intestinal and renal uptake of TH may be genetically impaired in some 
individuals who develop WE. Some reported that the presence of a genetically conditioned 
low affinity TK may predispose to WE (Mukherjee, Svoronos et al. 1987). Since no 
differences in the nucleotide sequence of the encoding gene or in the amino acid sequence 
were identified, it has been proposed that the biochemical difference in the activity of TK 
may be caused by posttranscriptional changes or by differences in the three-dimensional 
conformation (McCool, Plonk et al. 1993). Another possible genetic factor predisposing to 
WE is the mutation of the X-linked transketolase-like 1 gene (Coy, Dubel et al. 1996). Genetic 
variants of the enzymes involved in the metabolism of ethanol may also predispose to WE 
(Sechi and Serra 2007). Mutations in an untranslated regulatory region of SLC19A2 gene 
(also involved in TH-responsive megaloblastic anemia) seem to be involved in the genetic 
predisposition to WE (Guerrini, Thomson et al. 2005). These genetic defects might explain 
the inability of certain individuals to cope with borderline-low TH deficiency. A WE-like 
phenotype caused by defects of the SLC19A3 gene (typically involved in childhood onset 
biotin-responsive basal ganglia disease) has been reported in two Japanese brothers. Both of 
them were compound heterozygote for the K44E and E320Q mutations. These mutations 
were not found in 192 ethnically matched controls (Kono, Miyajima et al. 2009).  
In conclusion, one or more genetic mutations occurring in the same individual probably 
cause subtle alterations in the neuroglial and/or neuronal TH transporter systems and/or 
in the activity of THDP dependent enzymes, that in the presence of absolute or relative 
THDP deficiency and/or Mg deficit lead to the development of WE (Thomson and 
Marshall 2006).  
4. Neuropathology 
The anatomical pathology of WE is well described, mostly due to the large number of 
necroptic studies performed. The macroscopic and microscopic characteristics depend on 
the stage and severity of the disease (Sechi and Serra 2007). WE may coexist with typical 
hepatic encephalopathy findings, the neuropathologic differential diagnosis being 
sometimes difficult (Caine, Halliday et al. 1997). To the best of our knowledge, WE 
electronic microscopy data are not available. Gross findings consist of bilateral symmetrical 
grayish discoloration, congestion and recent petechial hemorrhages involving the 
periaqueductal grey matter, mamillary bodies, and medial thalamus. The most frequent 
lesion observed (up to 75% of the cases) is spongy or granular brown-grayish discoloration 
of the thalamus (Victor, Adams et al. 1971). The presence of punctuate hemorrhages in the 
mamillary bodies is highly specific (Thorarinsson, Olafsson et al. 2011). Larger hemorrhages 
(up to 8 mm in diameter) found in the vicinity of the third and the fourth ventricle have 
been reported in at least two cases with otherwise typical histopathological and clinical 
presentation (Rosenblum and Feigin 1965; Vortmeyer, Hagel et al. 1992). Rarely, 
discoloration may be observed in the reticular formation of the midbrain, corpora 
quadrigemina and in the cortex. The cerebellum may show atrophy of the vermis. Typically 
the brain has normal weight, though in chronic alcoholics significant atrophy may exist.  
Its surface has normal appearance. The lateral ventricles may sometimes be dilated, most 
likely secondary to chronic alcohol abuse-related atrophy (Victor, Adams et al. 1971; Harper 
1979). Atrophy of the corpus callosum has been reported in both alcohol and non alcohol 
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related WE. The extent and the location of callosal atrophy seems to vary in relationship 
with alcohol consumption (Lee, Jung et al. 2005). In a significant number of cases gross 
examination alone does not reveal any lesions (Harper 1979; Donnino, Vega et al. 2007).  
Microscopically, the typical aspect of the WE lesions consists of symmetric 
microhemorrhagic and/or necrotic lesions and microglia proliferation affecting 
symmetrically the cerebral midline regions, mainly the thalamus, mamillary bodies, 
periaqueductal region, hypothalamus, cerebellar vermis, proximity of the third ventricle and 
the floor of the fourth ventricle (Victor, Adams et al. 1971; Fattal-Valevski 2011). The 
distribution of the lesions is highly localized. The medial dorsal thalamic nucleus and the 
mamillary bodies are affected in virtually all patients (Victor, Adams et al. 1971). The locus 
ceruleus, oculomotor and vestibular nuclei and the medial aspect of the thalamus are also 
frequently involved. In the most severe cases extensive necrosis of the affected areas is 
observed. In the mild cases only loss of myelin and to a lesser degree of neuronal bodies is 
noticed. The number of astrocytes and macrophages is commonly increased. Focal 
microhemorrhages are sometimes found. Macrophages containing hemosiderin (thus 
indicating previous hemorrhage) may be encountered. Sometimes lesions consisting of 
patchy or diffuse neuronal loss and Alzheimer type II astrocytic proliferation (typically seen 
in hepatic encephalopathy) are found in the hippocampus, fornix, septal regions and 
cerebral cortex. The acute WE lesions are characterized by vascular congestion, petechial 
hemorrhages and astrocytes swelling affecting mainly the brainstem and the thalamus. The 
older lesions are characterized by demyelination, gliosis, edema and loss of neuropils in 
spite of the relative preservation of neurons (Sechi and Serra 2007). The capillaries are 
dilated and are surrounded by edema and microhemorrhages. Some have observed 
capillary proliferation, while others did not. Cerebellar vermis lesions compatible with those 
found in the alcoholic cerebellar degeneration – i.e. selective loss of Purkinje cells - are found 
in about half of the cases (Thorarinsson, Olafsson et al. 2011). Edema, microhemorrhages 
and possible necrosis involving the optic nerve may rarely be found (Li and Rucker 2010). 
The chronic lesions usually affect the mamillary bodies and the dorsomedial thalamic 
nuclei. Atrophy of the mamillary bodies is highly specific for the sequelae of WE, being 
found even by macroscopic examination in the majority of the cases. Widening of the third 
and fourth ventricle and of the aqueduct is also observed in the late and sequelar stages. 
Microscopically there is proliferation of astrocytes, tissue destruction and gliosis, while the 
capillary endothelium is normal and microhemorrhages are absent (Donnino, Vega et al. 
2007; Thorarinsson, Olafsson et al. 2011). Swelling, disruption and hyperplasia of the 
choroid plexus has been reported in AIDS patients with WE (Boldorini, Vago et al. 1992). 
Frequently the peripheral nerves have identical aspect with that seen in beriberi, i.e. distal 
demyelination. The spinal cord may be affected, a decrease in the anterior horn cells and 
sometimes involvement of the anterior and posterior roots being encountered (Sechi and 
Serra 2007).  
5. Physiopatogeny 
In spite of the fact that an animal model is easily designable the physiopathological 
pathways that lead to WE are incompletely understood. The disruption of the THDP 
dependent enzymatic activity in WE susceptible individuals results in highly localized 






lesions’. Providing the disruption is not promptly restored, the ‘biochemical lesions’ are 
replaced by irreversible structural damage (i.e. necrosis). The typical lesions are located 
symmetrically in the periventricular and periaqueductal grey areas. The clinical picture is 
highly correlated with the topography of the lesions (Hazell and Butterworth 2009). If the 
THDP dependent enzymatic activity is resumed WE is cured (with or without sequelae). 
Otherwise, exitus commonly occurs (Sechi and Serra 2007). WE develops rapidly, being 
usually induced by severe short-term TH deficiency. Persistent or recurring mild THDP 
deficiency may lead to a chronic evolution (Thomson and Marshall 2006). The reason for the 
specific selective topographic distribution of the WE lesions is still a matter of debate. A 
high cellular specificity seems to exist, the astrocytes being the most susceptible to THDP 
deficiency. The degree of activity reduction seems to be different for each THDP-dependent 
enzyme and strongly related to the cell’s type. Intuitively, one may assume that the most 
affected brain regions are those with higher metabolic demands, and thus with higher TH 
requirements. Nevertheless, the cortex is most often spared (Butterworth, Kril et al. 1993; 
Hazell 2009). Some have proposed that the periventricular areas are affected to a greater 
degree due to the parenchyma consequences of the high CSF glutamate levels (Nixon 2008). 
Others have observed that the occurrence of adult neurogenesis may be one of the main 
differences between the affected regions and the cortical areas, rendering the former more 
susceptible (Zhao, Pan et al. 2009). Pre and post-transcriptional regulation of the genes 
encoding the THDP-dependent apoenzymes may possibly be involved (Hazell 2009; Hazell 
and Butterworth 2009). 
A chronologic sequence of the physiopathological changes encountered in WE has been 
proposed. Accordingly, after about 4 days of THDP deficiency the activity of the astrocytic 
aKGDH decreases resulting in cytotoxic edema. After 7 to 10 days a decrease in the activity 
of the astrocytic TK occurs. The astrocytic dysfunction leads to the increase in extracellular 
glutamate levels (resulting in excitocytotoxicity), accumulation of free radicals and cytokines 
and loss of the osmotic gradients. Endothelial cell dysfunction resulting in increase nitric 
oxide (NO) production occurs. The BBB is disrupted and glial and neuronal vasogenic 
edema appears. After about 14 days focal lactic acidosis, neuronal DNA fragmentation and 
neuronal necrosis occur (Sechi and Serra 2007). According to a recent in vivo animal 
imagistic study the first observable consequence of TH deficiency may be the dysfunction 
the choroid plexus leading to blood-CSF barrier alteration (Nixon, Jordan et al. 2008). The 
earliest biochemical change reported in experimental WE animal models consists of 
decreased astrocyte aKGDH activity and the first histopathological finding observed is 
exclusive neuroglial damage (Butterworth 1986). The THDP deficiency has a profound effect 
on the functional integrity of the astrocytes. One of the consequences of the decreased 
aKGDH activity is the impairment of the Krebs cycle leading to cellular energetic failure. 
Increase oxidative stress and lactate production occur, the latter leading to focal acidosis. 
Increased lactic acid levels are observed in the areas which subsequently develop 
histological lesions and the magnetic resonance spectroscopy studies demonstrate a 
characteristic lesional lactate peak (Butterworth 1989; Pannunzio, Hazell et al. 2000; 
Donnino, Vega et al. 2007; Sullivan and Pfefferbaum 2009). The disturbed function of the 
astrocytic membrane results in the alterations of the ionic and osmotic gradients, and thus, 
in cytotoxic edema. The impairment of the astrocyte function along with the subsequent 
endothelial dysfunction causes BBB dysfunction that leads to vasogenic edema (Hazell and 
Butterworth 2009). The endothelial dysfunction causes increased production of NO and 
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cytokines, the former exacerbating the BBB dysfunction (Sechi and Serra 2007). The astrocyte 
dysfunction leads to increased extracellular glutamate levels mainly due to the suboptimal 
astrocyte uptake, the oxidative stress leading to the downregulation of the astrocytic 
glutamate 1 (GLT1) and glutamate-aspartate transporters (Langlais and Zhang 1993; 
Danbolt 2001; Hazell, Rao et al. 2001; Nixon 2008; Hazell and Butterworth 2009). The 
accumulating extracellular glutamate leads to N-methyl D-aspartate receptor (NMDA-R) 
mediated excitocytotoxicity resulting in neuronal loss (Todd and Butterworth 1998). Several 
studies have provided strong evidence for the presence of excitotoxic mediated cell death in 
TH deficient brains (Hazell, Butterworth et al. 1993; Langlais and Zhang 1993). The 
glutamate neuronal overstimulation leads to the accumulation of high extracellular 
potassium (K) levels. The elevated K is uptaked from the extracellular space by the 
astrocytes which consequently swell even more via osmosis. This leads to the further 
impairment of the astrocytes function which become unable to adequately buffer the 
accumulating extracellular glutamate and K, with deleterious consequences on the 
surrounding neurons (Kimelberg, Goderie et al. 1990; Kimelberg, Rutledge et al. 1995). The 
excess of glutamate is also removed from the interstitial fluid by passive diffusion in the CSF 
followed by choroid plexus active clearance. Decreased aKGDH activity in the ependymal 
and endothelial cells of the choroid plexus may lead to impairment of the energy dependent 
processes, and thus impairment of the CSF glutamate clearance. Therefore, as already 
mentioned, the glutamate levels may be additionally increased in the periventricular areas. 
The excessive presence of CSF glutamate may lead to further impairment of the choroid 
plexus activity (Nixon 2008). Increased aquaporin 4 (AQP4) gene expression has also been 
reported to occur in astrocytes, possibly being induced by the local lactic acidosis. This 
causes upregulation of the AQP4 membrane water channels which facilitate the astrocytic 
edema (Morishima, Aoyama et al. 2008; Hazell 2009; Hazell and Butterworth 2009). The loss 
of the aKGDH activity may also lead to a decrease in the GABA levels. The decreased GABA 
levels may exacerbate the glutamate mediated excitotoxic brain injury (Heroux and 
Butterworth 1988). It has been reported that WE patients may have increased neuronal 
peroxidase activity and decreased superoxide dismutase activity (Slekar, Kosman et al. 
1996). The presence of oxidative stress appears to be associated with selective 
neurodegeneration (Calingasan, Chun et al. 1999). The pathogenic role of the oxidative 
stress in WE is supported by the neuroprotective effects of selegiline on the THDP 
deficiency induced brain injury (Slekar, Kosman et al. 1996; Hazell and Butterworth 2009). 
The production of NO increases rapidly in the TH deprived brain, especially in the medial 
thalamus, possibly as a consequence of aKGDH activity impairment. Elevated NO levels 
may have physiopathological significance exacerbating the oxidative stress (Fattal-Valevski 
2011). The decreased activity of the global nitric oxide synthase (NOS), reported by some to 
selectively affect the thalamus and cerebellum of TH deficient animals, may be a marker of 
the neuronal loss (Rao, Mousseau et al. 1996). Due to the impairment of the PPP secondary 
to THDP deficiency the local reducing activity decreases and ribose production diminishes.  
This results in increased oxidative stress and respectively in impaired nucleotide, nucleic 
acids, coenzymes and polysaccharides synthesis (Slekar, Kosman et al. 1996). In the absence 
of adequate PDH activity, pyruvate cannot be converted to acetyl-CoA, thus rendering 
oxidative phosphorylation inefficient. This exacerbates the already present lactic acidosis. It 
has been reported that in the presence of TH deficiency the susceptible and non-susceptible 
brain regions exhibit a significant upregulation in inflammatory genes transcription (Hazell 






selectively increased in the susceptible brain areas of the animals with symptomatic TH 
deficiency. The increased expression of cox-2 is accompanied by an increase in 
prostaglandin E2 (PGE2) levels which is not observed in the presimptomatic stages. The 
administration of the cox-2 inhibitor nimensulide decreases PGE2 levels but leads to the 
exacerbation of the neuronal injury, suggesting that PGE2 may exert a neuroprotective role. 
The differences in the expression of the inflammatory related genes in the different brain 
regions may be one of the factors leading to the selective brain vulnerability (Gu, Desjardins 
et al. 2008). If the TH deficiency persists for more than two weeks DNA fragmentation 
triggering apoptosis occurs in the thalamic neurons (Pannunzio, Hazell et al. 2000). In a 
study on cultured neuroblastoma cells TH deficiency resulted in the accumulation of 
glutamate due to aKGDH reduced activity. Overt signs of necrosis (i.e. condensed 
chromatin, decreased oxygen consumption, and uncoupled mitochondria with disorganized 
cristae) were observed. The normalization of the TH levels resulted in the reversal of all 
changes, mitochondrial morphology being recovered within an hour (Bettendorff, Goessens 
et al. 1997). This suggests that the slowing of the Krebs cycle is the main cause of the 
biochemical lesions induced by TH deficiency. In vivo, the clinical improvement following 
TH administration corresponds to the improvement in the PDH activity (Thomson and 
Marshall 2006). This suggests that in vivo the impairment in PDH activity has great 
consequences, possibly by its effect on the Krebs cycle. It was proposed that the impairment 
of the PDH activity may lead to the impairment of acetylcholine synthesis, though several 
studies failed to confirm this hypothesis (Heinrich, Stadler et al. 1973). However, three case 
reports suggest that WE patients may benefit from the administration of the 
acetylcholinesterase inhibitor donepezil (Thomson and Marshall 2006). The possible role of 
other neurotransmitters in the physiopathology of WE has been speculated. Some have 
reported that changes in GABA, glutamate, and aspartate levels may occur, as their 
production requires proper glucose metabolism (Hazell, Butterworth et al. 1993). Others 
reported no impairment in these neurotransmitters levels (Fattal-Valevski 2011). Decreased 
levels of the serotonin metabolite 5-hydroxyindoleacetic acid where found in the CSF of WE 
patients, while some studies found that cerebellar extracellular serotonin levels were 
increased due to decreased cellular uptake (Plaitakis, Van Woert, et al. 1978). 
It has been observed that alcohol related WE is more frequently associated with lesions with 
typical topography, irreversible brain damage and KS. Several possible physiopathological 
explanations have been proposed. The alcoholics may have recurrent episodes of mild TH 
deficiency that may render the brain’s affected areas more vulnerable to future injury 
and/or may have persistent subclinical TH deficiency leading to a chronic evolution. In a 
study on rhesus monkeys the recurrent stereotypic rapid variation of the TH levels ranging 
from very low to very high led to the progressive worsening of the TH deficiency-induced 
symptoms, in spite of their complete resolution after TH administration (Thomson and 
Marshall 2006). It seems that the length of a single TH deprivation period and not their 
number determines the severity of the induced structural brain damage. The effects are 
cumulative, the symptoms of TH deprivation appearing sooner with each episode (Witt 
1985; Ciccia and Langlais 2000). Some suggested that chronic alcohol exposure and/or TH 
deficiency may render certain brain areas (that are not typically affected in alcoholics but are 
often affected in non alcoholics) more resistant to TH deficiency. It has been proposed that 
large and repeated fluctuations in TH levels may impair the capacity of the brain to cope 
with low TH levels and in this respect some have suggested that the administration of high 
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TH doses in alcoholic patients with asymptomatic TH deficiency may be deleterious 
providing a lifestyle change does not occur. Chronic ethanol exposure blocks the NMDA-R 
at the glutamate site. This results in the upregulation of the glutamate receptors. Alcohol 
withdrawal may increase TH requirements and may exacerbate the glutamate mediated 
excitocytotoxic injury, the abundant extracellular glutamate acting on an upredgulated 
NMDA-R population which is no longer blocked by ethanol. A preliminary clinical study 
suggests that the NMDA antagonist memantine might be beneficial in WE (Harper 2006). It 
has been suggested that ethanol may accelerate the cerebral metabolism of TH and that 
chronic alcohol exposure may reduce the TK’s affinity for THDP (Laforenza, Patrini et al. 
1990). Alcoholics may frequently have other vitamin and mineral deficiencies that may 
contribute to the WE particularities (Ihara, Ito et al. 1999). Since pyridoxine and riboflavin 
are necessary for the conversion of glutamate to GABA, WE alcoholics may have an 
additional increase of the extracellular glutamate levels (Thomson, Cook et al. 2002). 
Recurrent seizures and/or head trauma are more frequent in alcoholics and may subtlety 
alter the brain’s capacity to withstand additional metabolic injury. Previous episodes of 
hepatic encephalopathy may render the brain more susceptible to TH deficiency (Caine, 
Halliday et al. 1997).  
6. Clinical presentation and anatomo-clinical correlations 
The classical hallmark of WE consists of ocular motility signs, stance and/or gait ataxia and 
mental status changes having acute or subacute onset. The absence of all these signs may 
occur in approximately 16% of the cases, though usually at least one of them appears at 
some point in the course of the disease. When present, the stance and/or gait ataxia usually 
precedes the onset of the other symptoms. The ocular motility signs have been reported in 
29 to 90% of the cases, ataxia has been reported 23 to 70% and mental status changes have 
been reported in 82 to 90% (Harper, Giles et al. 1986; Victor 1989; Ogershok, Rahman et al. 
2002). The symptoms may develop simultaneously or in a succeeding manner, over a 
shorter or longer period of time. In a significant number of patients, typical fundoscopic 
findings are present (Doss, Mahad et al. 2003). Other less specific WE manifestations include 
anorexia, vomiting, hypotension, orthostatic hypotension, hypothermia, hyperthermia, 
miosis, urine retention, tachycardia, dyspnea, visual disturbances and sensitive ataxia 
(Victor 1989; Donnino, Vega et al. 2007). Except for the motor ocular and vestibular nerves 
nuclei, WE is not commonly responsible of cranial nerve involvement. However, bilateral 
peripheral facial paresis has been reported. Also, dysphagia and dysphonia in association 
with vagus nerve degeneration have been reported in severely malnourished WE patients 
(Novak and Victor 1974). The presence of the Babinsky reflex has been very rarely observed. 
Signs and symptoms consistent with polyneuropathy are present in up to 82% of WE 
patients, and usually have acute or subacute onset, closely preceding the onset of WE. 
Commonly the clinical signs are typical for peripheral motor and sensitive involvement, the 
lower extremities being significantly more frequently and severely affected than the upper 
extremities. Concomitant autonomic neuropathy is rare; it leads to orthostatic hypotension if 
the sympathetic system is affected and to urinary retention if the parasympathetic system is 
affected. Overt cardiovascular beriberi only rarely coexists, but mild forms have been 
reported. The cardiovascular involvement caused by TH deficiency is responsible of either 






output cardiac failure with concomitant hypotension and acidosis. The latter may have 
dramatic hyperacute evolution, i.e. the so-called shoshin beriberi (Thorarinsson, Olafsson et 
al. 2011). Gastrointestinal beriberi, resulting in abdominal pain and other digestive 
symptoms, may rarely coexist with WE, especially in children (Donnino 2004). The so-called 
subclinical TH deficiency states may be responsible of nonspecific symptoms such as 
recurrent headaches, irritability, abdominal discomfort and, in children, decline in growth 
rate. Late manifestations of untreated WE include KS (mamillo-thalamic involvement), 
spastic paresis (frontal cortex and/or pyramidal tracts involvement), hyperthermia 
unresponsive to antipyretics (anterior hypothalamus involvement), and increased muscular 
tone with nuchal rigidity and chorea (basal ganglia and/or mesopontine tegmental 
involvement) (Ogershok, Rahman et al. 2002; Donnino 2004; Harper 2006; Sechi and Serra 
2007). Myoclonus has been reported in several neuropathologically confirmed WE cases, 
clinically diagnosed as Creutzfeldt-Jakob disease (Bertrand, Brandel et al. 2009). 
The ocular motility signs encountered in WE are the consequence of lesions involving the 
oculomotor, abducens and vestibular nuclei, the pontine tegmentum and the internuclear 
fibers (Victor 1989; Ogershok, Rahman et al. 2002; Harper 2006; Sechi and Serra 2007). 
Typically they consist of nystagmus, bilateral lateral rectus muscle palsy and impairment of 
conjugate gaze. However, these three ocular signs are only rarely seen together. The 
nystagmus is the most common ocular finding, being reported in 10 to 85% of the patients 
(Harper, Giles et al. 1986; Ogershok, Rahman et al. 2002). Gaze evoked horizontal bilateral 
nystagmus is the type of nystagmus most frequently observed. Vertical nystagmus evoked 
by upward gaze may coexist, but the presence of isolated vertical or rotator nystagmus is 
unusual. Lateral rectus palsy is the most frequent ophtalmoplegia, occurring in 4 to 54% of 
WE cases. It is virtually always bilateral, but not necessarily symmetric. It is associated with 
diplopia and internal strabismus (Ogershok, Rahman et al. 2002). Other ocular muscles 
palsies may rarely occur. Conjugate gaze palsy of variable intensity may be found in up to 
44% of the patients. Vertical gaze palsy occurs only exceptionally, isolated paralysis of 
downward gaze being seldom reported (Harper 2006). The ocular motility signs show the 
most rapid reversibility, ophtalmoplegia disappearing even as soon as six hours after 
intravenous TH administration. Commonly, complete recovery occurs in less than 7 days. In 
up to 60% of the cases the resolution of the ophtalmoplegia was reported to occur in less 
than a day. This may be used as clinical diagnostic test, supporting the WE diagnosis (Victor 
1989; Sechi and Serra 2007). The nystagmus recovers more slowly and was reported to 
persist for at least 2 years in 60 % of the treated patients (Thorarinsson, Olafsson et al. 2011). 
Pupillary dysfunction, ptosis, impaired convergence and internuclear ophtalmoplegia are 
very rarely found. The pupils are often spared except in the presence of hypothermia or in 
the final stages when they may be anisocoric, miotic and non-reacting (Victor 1989; 
Ogershok, Rahman et al. 2002; Harper 2006; Sechi and Serra 2007). Fundoscopic findings 
comprising of retinal hemorrhages, papillary edema or disc pallor are commonly seen in WE 
patients and have been reported even by Wernicke himself. Some have proposed that these 
are caused by a TH deficiency optic neuropathy associated with WE. Usually these 
fundoscopic changes are not associated with symptoms. Rarely disturbances of vision 
consisting of decreased visual acuity, scotomas and even bilateral blindness have been 
reported (Doss, Mahad et al. 2003; Surges, Beck et al. 2007).  
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The ataxic syndrome encountered in WE is the consequence of propriocerebellar and 
vestibulocerebellar dysfunction. Most frequently, the WE cerebellar lesions are located in 
the superior vermis. However, central vestibular ataxia and disequilibrium due to central 
vestibular dysfunction and peripheral proprioceptive ataxia due to polyneuropathy may 
coexist. Typically variable degrees of ataxia of stance and gait, ranging from barely 
noticeable tandem walking impairment to inability to walk or stand, are found. Since TH 
deficiency usually does not lead to cerebellar hemispheric lesions, limb ataxia and other 
cerebellar signs are only exceptionally seen (Victor 1989; Ogershok, Rahman et al. 2002; 
Harper 2006). However, in acute settings mild limb ataxia might be present. WE patients 
may associate alcoholic cerebellar degeneration that frequently causes limb ataxia (Antunez, 
Estruch et al. 1998). Ataxic speech has rarely been reported in WE patients. The vestibular 
dysfunction is very common in acute WE, the ice-water caloric testing and the vestibulo-
ocular reflex showing impairment in virtually all cases. It has been proposed that the 
vestibular dysfunction may be responsible of the postural imbalance of WE patients. Usually 
vertigo and/or hearing loss are not present (Doss, Mahad et al. 2003). Commonly the 
cerebellar and vestibular dysfunctions begin to improve after 2 to 6 days. In a significant 
number of cases the gait disturbances persist indefinitely (Sechi and Serra 2007). 
The mental status changes encountered in WE patients are probably the consequence of the 
bilateral thalamic, mamillary bodies and rarely head of the caudate nuclei lesions. The 
connections between the left-sided anterior thalamus and the ipsilateral mamillary body, 
documented by functional MRI (fMRI) studies, have been reported to be impaired in those 
with WE, and to a lesser degree in alcoholics without WE (Kim, Ku et al. 2009). The critical 
pattern of the lesions that results in KS has not been identified, but is agreed upon that 
bilateral involvement of the limbic circuits is necessary. Some proposed that the concomitant 
bilateral involvement of the hippocampal (medial limbic) and amygdaloid (basolateral 
limbic) circuits results in KS. According to the necroptic and imagistic studies, KS is 
associated with lesions involving the anterior, mediodorsal and/or midline thalamus, 
mamillary bodies and/or the mamillo-thalamic tracts. All these may result in the disruption 
of the above mentioned circuits (Mishkin 1978; Mair, Warrington et al. 1979; Kopelman 
1995). The fMRI based studies on patients with acute or persistent anterograde amnesia due 
to WE revealed absence of hippocampal activation during encoding or retrieving tasks in 
spite of lack of MRI evidence for medial temporal structural damage, and in the presence of  
fMRI proof of intact perception, attention and judgment (Caulo, Van Hecke et al. 2005) and 
positron emission tomography (PET) studies  reported the presence of significant glucose 
hypometabolism in the limbic circuits, bilateral thalamic nuclei, mesial prefrontal cortices and 
fronto-temporo-parietal cortices (Joyce, Rio et al. 1994; Aupee, Desgranges et al. 2001; 
Fellgiebel, Scheurich et al. 2003). The mental status changes may range from apathy, 
hypoprosexia, disorientation, confusion, mild hypomnesia, anterograde and retrograde 
amnesia and confabulations (typically spontaneous) to hallucinations and behavioral 
disturbances. Altered states of consciousness ranging from somnolence and stupor to coma 
also occur, the latter usually being related to bilateral thalamic or head of caudate nuclei 
lesions. Stupor and coma may be the presenting symptoms more frequently than expected, 
being reported in up to 10% of the cases (Lana-Peixoto, Dos Santos et al. 1992; Thomson, Cook 
et al. 2008). Untreated comatose patients usually die after several days (Harper, Giles et al. 
1986; Victor 1989). Confusion seems to be the most frequent symptom, being reported in up to 






comprises of anterograde amnesia affecting the episodic memory and in variable degree the 
semantic memory (the working memory is intact and so is the secondary implicit memory!), 
retrograde temporally graded amnesia and confabulations (spontaneous in the early stages, 
latterly provoked by memory challenges) occurring in the absence of other significant 
cognitive impairments (language, visuo-perceptual functioning, problem solving, and 
judgment intact!), usually in the absence of insight (Yoneoka, Takeda et al. 2004; Kopelman, 
Thomson et al. 2009). Some of the mental status changes may be caused by the comorbid 
conditions (e.g. delirium tremens). In WE alone, agitation may rarely be seen. Seizures may 
occur, most likely in relationship with the comorbid conditions (e.g. alcohol withdrawal), 
though cortical lesion may rarely be encountered. Some have proposed that the seizure 
threshold may be lowered due to the presence of excessive glutamatergic stimulation. In a 
significant number of cases the mental status changes are only partially reversible, KS being a 
frequent sequel, especially in alcoholics. The mental status changes begin to improve after a 
few days to a week of treatment, the confusional syndrome being the first to recover. Sequels 
may occur, especially in those with KS. WE patients have increased risk of sudden death. The 
risk of sudden death is not necessarily related to WE, the cardiovascular dysfunction due to 
TH deficiency or comorbid conditions (e.g. alcoholic cardiomyopathy) possibly being 
responsible (Harper 2006; Thomson and Marshall 2006; Sechi and Serra 2007). 
Particularities of the clinical presentations of WE in alcoholics, non alcoholics and other 
selected sub-groups have been reported. However, no typical syndromes have been 
identified and part of the differences may be related with the associated conditions. The 
classical triad and KS occur more frequently in alcoholics. The polyneuropathy, seizures and 
sudden death are also encountered more often in alcoholics. Typically alcoholics with WE 
are malnourished and underweight, though overweight beer drinkers are also prone to WE. 
The onset of WE in alcoholics is usually subacute and the evolution might be chronic in 
those with recurrent mild, subclinical TH deficiency episodes (Harper, Giles et al. 1986; 
Victor 1989; Harper 2006). Most of the cases of necropsy confirmed WE presenting with 
coma were reported in alcoholic patients (Thomson, Cook et al. 2008). The non alcohol-
related WE usually has acute onset. Neurologic disturbances reversible after TH 
administration have been reported to occur in obese patients after 14 to 34 days of 
therapeutic fasting. The first symptoms where atypical and consisted of drowsiness, 
dizziness, apathy, psychosis and visual disturbances (Ogershok, Rahman et al. 2002). 
Individuals that underwent bariatric surgery have been reported to develop WE in 2 to 4 
weeks after the procedure, those with persistent vomiting appearing to be more susceptible. 
Cases occurring as late as 12 to 24 weeks have been reported. The clinical picture was 
atypical. In those with non-bariatric gastrointestinal surgery WE develops in 2 to 8 weeks 
after the procedure, but cases occurring as early as 2 weeks or as late as 20 years have been 
reported. The risk of developing WE was reported to be higher in those with weight loss 
greater than 7 kilograms per month (Foster, Falah et al. 2005; Dallal 2006; Serra, Sechi et al. 
2007; Aasheim 2008). Patients with severe hyperemesis gravidarium were reported to 
develop WE after 7.7 +/- 2.8 weeks of persistent vomiting. The clinical triad was present in 
half of the cases. The resolution of symptoms was slow in spite of adequate treatment and 
sequelae commonly occurred. In almost half of the cases the pregnancy was loss (Chiossi, 
Neri et al. 2006). Hunger strikers were reported to develop symptoms consistent with WE 
(nystagmus and axial ataxia) after about 6 weeks of fasting. The clinical triad occurred in 
almost a quarter of patients. Peripheral nervous system involvement occurred, but was less 
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prominent than the central nervous system involvement (Basoglu, Yetimalar et al. 2006). War 
prisoners on a TH deficient diet developed anorexia, nausea, vomiting, diplopia, insomnia, 
anxiety, hypoprosexia, memory impairment, confusion, confabulation, hallucination and 
eventually coma (De and Lennox 1947). In infants the onset is usually hyperacute and exitus 
may rapidly occur. The first noted symptoms are constipation, vomiting, restlessness, followed 
by aphonia, absence of deep tendon reflexes, metabolic acidosis, meningeal irritation, 
convulsions and heart failure (Fattal-Valevski, Kesler et al. 2005). 
7. Imagistic findings 
Brain imagistic investigations are required in virtually all patients presenting with a clinical 
picture suggestive of WE. The imagistic evaluation methods used in the current clinical 
practice are the brain X-ray computed axial tomography (CT) and the magnetic resonance 
imaging (MRI), the latter providing more information. Other structural and functional 
imagistic modalities have minute relevance for the management of WE patients, are not 
widely available and are expensive, therefore being mainly reserved as research tools (Sechi 
and Serra 2007). They will not be discussed. The MRI techniques commonly used for the 
assessment of WE are T1, T2 and T2 based modalities (e.g. late echo T2 and FLAIR), 
accompanied or not by contrast administration (i.e. gadolinium). Less frequently used, but 
very informative providing the correlation with the apparent diffusion coefficient (ADC) is 
made, is the diffusion weighted imaging (DWI). The typical WE lesions have high T2 and 
FLAIR signal (hyperintensity) and normal or low T1 signal (iso- or hypointensity). The 
FLAIR acquisition technique eliminates the hyperintense T2 signal of the CSF and therefore 
even small periventricular and periaqueductal high signal lesions become obvious. The 
contrast enhancement is the imagistic expression of BBB disruption (Zuccoli, Gallucci et al. 
2007; Sullivan and Pfefferbaum 2009). The DWI is an acquisition technique in which the 
signal from unbound water is suppressed, thus areas with high concentrations of unbound 
water appearing as hypointense, while areas with low concentration of unbound water 
appear as hyperintense (i.e. restricted diffusion areas). The echo-planar DWI technique 
allows very short examination times, making its use practical even in acute settings. The 
typical WE lesions appear hyperintense on DWI, as if diffusion were restricted. When the 
DWI hyperintensity corresponds to a T2 hyperintensity, the DWI finding may be the 
consequence of the so-called ‘T2 hyperintensity shine through effect’ and may not truly 
represent restricted diffusion. The presence of diffusion restriction is confirmed by 
confronting the correspondent values of the ADC, which should be low, and the ADC map, 
which should show hypointensity. In the case of ‘T2 hyperintensity shine through effect’ the 
ADC value is normal or high and the ADC map shows iso- or hyperintensity. In the very 
early stages the WE lesions have true restricted diffusion, translating the presence of 
cytotoxic edema in the absence of vasogenic edema. Considering that the DWI is very 
sensitive for cytotoxic edema, this MRI technique might be of great use for the very early 
identification of WE lesions. Late, atrophic WE lesions also show restricted diffusion 
(Halavaara, Brander et al. 2003; Lapergue, Klein et al. 2006; Unlu, Cakir et al. 2006; Zuccoli, 
Santa Cruz et al. 2009). The most frequent conventional MRI findings in active WE are 
bilateral, symmetric, contrast enhancing or not, T2, late echo T2 and/or FLAIR 
hyperintensity of the mamillary bodies, anterior and medial nuclei of the thalamus, 






superior colliculi, caudate nuclei, midbrain and cerebellum (Schroth, Wichmann et al. 1991; 
Chu, Kang et al. 2002; Zhong, Jin et al. 2005; Unlu, Cakir et al. 2006; Zuccoli, Gallucci et al. 
2007; Zuccoli, Cravo et al. 2011). The characteristics of the MRI lesions change along the 
course of the disease. The earliest imagistic changes are probably those reflecting cytotoxic 
edema, followed by contrast enhancement reflecting BBB disruption, and byT2 and FLAIR 
signal changes reflecting the presence of vasogenic edema. In most of the cases the 
mamillary bodies appear to be the first structure involved. Bilateral mamillary body 
restricted diffusion followed by contrast enhancement and by FLAIR and T2 signal changes 
might be the chronology of the earliest MRI findings, though, as recently argued by one 
author, choroid plexus contrast enhancement may precede the other MRI changes. 
Providing TH is supplied, the MRI findings may disappear as early as two days. In the early 
stages the typically injured areas show restricted diffusion. Restricted diffusion of the 
corpus callosum’s splenium has also been reported (Loh, Watson et al. 2005). The atrophy of 
the mamillary bodies, thalamus and cerebellar vermis may appear as soon as one week. The 
regions that frequently show contrast enhancement are the mamillary bodies, followed by 
the tectal plate, thalamus and periaqueductal grey matter. MRI signal changes involving the 
fornix, dorsal medulla oblongata, central pons, globus pallidus, putamen, frontal and/or 
parietal cortex, splenium, dentate nuclei, red nuclei and cranial nerve nuclei have rarely 
been reported (Park, Kim et al. 2001; Weidauer, Nichtweiss et al. 2003; Zuccoli, Gallucci et al. 
2007; Nixon, Jordan et al. 2008; Sullivan and Pfefferbaum 2009; Zuccoli; Zuccoli, Cravo et al. 
2011). WE cortical lesions comprising of linear more or less symmetric FLAIR and/or T2 
hyperintensities have also been described. A case of WE related obstructive hydrocephalus 
in the presence of otherwise typical MRI findings has been reported (Doss, Mahad et al. 
2003). To the best of our knowledge, the imagistic characteristics of WE-related optic 
neuropathy have not been presented. The imagistic sequelae of WE are scarcely described. 
Atrophy of the mamillary bodies, cerebellar vermis and less often of the thalamus 
(corresponding with third ventricular enlargement) has been reported. These are 
frequently found in alcoholics and correlate with the persistence of clinical findings. MRI 
evidence of mamillary bodies, pons, thalami, cerebellar hemisphere, superior vermis and 
hippocampal atrophy has been documented in KS patients with prior alcohol related WE.  
Except for hippocampal atrophy which, as reported by some, seems to occur only in KS 
patients, the other brain volume changes are also found in different degrees in alcoholics 
without KS and/or history of WE (Park, Kim et al. 2001). The typical conventional  
MRI findings described above are more commonly found in alcohol related WE. The 
bilateral mamillary body contrast enhancement, in association or not with incidental or 
subsequent mamillary body atrophy, shows a positive statistical correlation with alcohol 
consumption. Cortical, frontal lobe and cerebellar (especially vermian) atrophy are 
frequent CT and MRI findings in chronic alcohol abusers. These changes have higher 
incidence in alcoholics with concomitant WE than in alcoholics without WE. The MRI 
findings that may be related to chronic alcohol consumption and/or to prior WE episodes 
(e.g. mamillary body atrophy and possibly cerebellar atrophy) are also more frequently 
encountered in alcoholics. Besides the enlargement of the lateral ventricles, probably 
secondary to alcohol related cerebral atrophy, the enlargement of the third ventricle may 
be seen on the CT and MRI of alcoholic WE patients (Gallucci, Bozzao et al. 1990; 
Antunez, Estruch et al. 1998). Atypical MRI findings comprising of characteristic signal 
changes in the cerebellum, cranial nerves nuclei (especially abducens, facial, vestibular 
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and hypoglossal), red nuclei, dentate nuclei, caudate nuclei, splenium and cerebral cortex, 
that coexist or not with the above mentioned typical MRI findings are more frequently 
encountered in non alcohol related WE (Zhong, Jin et al. 2005; Liu, Fuh et al. 2006; Fei, 
Zhong et al. 2008; Zuccoli and Motti 2008). Commonly the pediatric WE patients have 
similar MRI findings as adult patients, but symmetric basal ganglia alterations with 
bilateral involvement of the putamen has been reported (Fattal-Valevski, Kesler et al. 
2005; Zuccoli, Siddiqui et al. 2010). 
 
Fig. 1. ‘Images from axial and coronal FLAIR sequence of the WK subject. Seven-day MRI 
study demonstrates signal abnormalities of the mammillary bodies (A) (stars), the medial 
aspect of the thalami (B, C) (arrows) and the fornix (B) (arrowheads). Five months later 
signal changes have almost completely disappeared (D) (arrows and arrowheads)’ – With 







In spite of the significant advances in imagistic and laboratory assessments WE remains 
mainly a clinical diagnosis. The paraclinical workup, comprising of brain MRI, blood TH 
assessments, routine blood tests and sometimes ancillary investigations, improves the 
accuracy of the diagnosis and is mandatory for the identification of potential comorbidities. 
The diagnosis is highly supported by the favorable response to parenteral TH 
administration, but is not excluded by the lack of it (Harper, Giles et al. 1986; Thomson, 
Cook et al. 2008). WE may present with a wide spectrum of nonspecific findings. Classically, 
the diagnosis requires the presence of the clinical triad consisting of ocular motility signs, 
stance and/or gait ataxia and mental status changes, having acute or subacute onset. 
However, the classic triad has been reported in less than a third of the adult WE cases (up to 
16% in necroptic retrospective studies!) and in 20% of the pediatric cases (Harper, Giles et al. 
1986; Victor 1989; Vasconcelos, Silva et al. 1999). Based on the data available in the literature 
regarding neuropathological proven WE cases, the prevalence of the classical triad is 
estimated to be 8.2% (Galvin, Brathen et al. 2010). The WE diagnosis may easily be 
overlooked, the 2010 EFNS guideline recommending the maintenance of a high index of 
suspicion for WE. ‘Operational clinical criteria for the classification of the chronic alcoholics 
and the identification of WE’ that take into account dietary deficiencies as predisposing 
factor for WE were proposed in 1997 by Caine. The intended purpose of these criteria was to 
accurately differentiate between alcoholics with WE (active and sequelae) and alcoholics 
without WE and between alcoholics with WE and alcoholics with hepatic encephalopathy. 
Since their intended applicability concerned only the alcoholic population they were not 
tested for reproducibility and variability in non alcoholics. According to these criteria the 
accurate ante-mortem identification of WE patients requires the presence of two of the 
following: dietary deficiencies (defined as: ‘undernutrition, vitamin deficiency’), eye signs 
(defined as: ‘ophtalmoplegia, nystagmus, gaze palsy’), cerebellar signs (defined as: 
‘unsteady, ataxia, cerebellar dysfunction’) and either altered mental status (defined as: 
‘disoriented, confuse, comatose, digit span abnormal’) or mild memory impairment (defined 
as: ‘mild-moderate memory problems, confabulating’). These criteria accurately differentiate 
between alcoholics with and without WE (though they do not differentiate between active 
WE and sequelae!) and also between alcoholics with WE and hepatic encephalopathy. Their 
use was estimated to increase the sensitivity (but not the specificity!) of the diagnosis of WE 
from 31% when using the classic triad to 100% (Caine, Halliday et al. 1997). Criteria for 
accurately identifying WE patients in the ‘accident and emergency department’ were 
proposed in 2001 by the UK Royal College of Physicians. According to their guideline, all 
patient presenting with any evidence of chronic alcohol use and any of the following: acute 
confusion, decreased consciousness level, ataxia, ophtalmoplegia, memory disturbance, 
hypothermia and hypotension and all patients presenting with acute alcohol intoxication or 
with delirium tremens should be presumed of having WE (Thomson, Cook et al. 2002). 
Though these criteria may accurately identify alcoholic patients with WE they are not 
applicable in the non alcoholic population. Since no better alternative exists, the 2010 EFNS 
guideline recommends the use of the ‘operational clinical criteria for the classification of the 
chronic alcoholics and the identification of WE’ proposed by Caine in 1997 for help in the 
diagnosis of WE in both alcoholics and non alcoholics (Galvin, Brathen et al. 2010). 
According to the 2010 EFNS guideline, brain imagistic investigations and measurement of 
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the total blood TH level should be included in the paraclinical workup of all those in which 
WE is suspected. The brain CT has low sensitivity (i.e. 13%) for the detection of WE lesions,  
but nevertheless it is of great utility in acute settings, the purpose of the imagistic 
assessments being not only to offer additional information supporting the diagnosis of WE, 
but to exclude other pathologies that might be responsible for the clinical presentation. The 
MRI offers better sensitivity than the CT for both acute and sequelar WE lesions. The 
sensitivity varies accordingly to the power of the magnet and to the technique of 
acquisition used. The estimated sensitivity for the conventional MRI techniques (i.e. T1, T2, 
FLAIR, paramagnetic contrast) is just above 50%, values of 53% and 58% being reported. 
Though it does not rule out WE, the MRI is probably the best method of confirming the 
diagnosis of WE, its specificity being estimated to be as high as 93% (Antunez, Estruch et 
al. 1998; Weidauer, Nichtweiss et al. 2003). The presence of low TH blood levels has low 
specificity for WE. The venous blood necessary for the laboratory assessments should be 
collected prior to TH administration (since is highly influenced by the recent TH intake) 
and kept away from light. The presence of low total TH or THDP levels is neither 
necessary nor sufficient for the diagnosis of WE. The recommended laboratory assays are 
the measure the total TH or THDP in the whole blood through various methods of HPLC 
(Talwar, Davidson et al. 2000; Thomson and Marshall 2006) The measurement of the 24 
hours urine TH levels has little utility in the diagnosis of WE. The level of TH in the urine 
collected in the following 4 hours after the administration of 1 mg intravenous TH may be 
used to estimate the tissue THDP state, but due to practical difficulties is not commonly 
used in clinical practice (Tallaksen, Bohmer et al. 1991; Tallaksen, Bell et al. 1993). Routine 
laboratory investigations are mandatory for the differential diagnosis of WE and for the 
identification of associated disorders. The routine laboratory investigations include the 
assessment of blood glucose levels, serum electrolytes, acute-phase reactants, liver, renal 
and hematologic status. Toxicology panels may be required in those presenting with acute 
confusion syndromes. The performance of additional testes (e.g. blood ammonia, thyroid 
tests, blood lipase, blood B12 levels, viral markers, immune tests) should be adapted to 
each patient. WE patients may show laboratory signs of dehydration and may have 
abnormal liver tests, hypomagnesaemia and anaemia (Traviesa 1974; Sechi and Serra 2007). 
The blood levels of lactic acid and pyruvate may be increased due to TH deficiency. Their 
measurement may be used for estimating the activity status of the THDP dependent 
enzymes, but they are neither specific nor sensible for TH deficiency or WE. Some have 
suggested that WE patients may associate lactic acidosis with or without respiratory 
alkalosis, leading to a characteristic acid-base pattern. In infants and in other selected 
susceptible patients the assessment of the acid-base equilibrium is required (Donnino, 
Miller et al. 2007). Lumbar puncture may be required especially in those associating 
hyperthermia. Commonly the routine analysis of the CSF of WE patients shows no 
particularities. In the later stages of WE mild protein elevation may occur (Victor 1989). 
The presence of protein 14-3-3 has been reported in several patients with WE (Michowitz, 
Copel et al. 2005; Bertrand, Brandel et al. 2009). CSF pleocytosis or protein levels above 100 
mg/dl should suggest an alternative or a coexistent disorder. The assessment of the 
electroencephalogram (EEG) may be required especially in those in which epileptic partial 
complex status is suspected. The EEG activity may be dominated by nonspecific diffuse 
slow waves in about half of WE patients (Victor 1989; Sechi and Serra 2007). Considering 
that the WE patients may associate cardiac pathology related or not to TH deficiency (e.g. 






an electrocardiogram and chest radiography should be routinely included in the 
paraclinical workup. WE patients may associate other encephalopathies (hepatic 
encephalopathy!), as well as brain unrelated diseases. The required workup should be 
adapted to each patient. It should be kept in mind that these comorbidities may 
predispose to WE and may correlate with the atypical presentations. Considering that WE 
patients commonly associate polyneuropathy and that WE may mimic Miller Fischer 
syndrome, nerve conduction studies may be required (Harper, Giles et al. 1986; Sechi and 
Serra 2007).  
9. Differentials 
The diferential diagnosis of WE is vast, comprising mainly of acute or subacute toxic, 
nutritional and metabolic encephalopaties, encephalitis and meningoencephalitis, and 
particular strokes. In certain cases diferentiating betwen acute or chronic WE and WE 
sequelae (including KS!) may be difficult. KS may have other etiologies than WE, and these 
shoud also be considered for the differential diagnosis. Among the acute or subacute toxic, 
nutritional and metabolic encephalopaties we emphasize acute alcohol intoxication, 
delirium tremens, acute Marchiafava-Bignami disease, subacute alcoholic cerebellar 
degeneration, acute alcoholic pellagra, hepatic encephalopaty, metronidazole 
encephalopaty. All of these may coexist with WE (Arbelaez, Pajon et al. 2003; Zuccoli, 
Pipitone et al. 2008; Thorarinsson, Olafsson et al. 2011). In certain clinical settings 
hypoglicemic coma, hypoxic or hypercapnic encephalopaty, hypertensive encephalopaty, 
severe hypophosphatemia, methyl bromide intoxication and sepsis asociated encephalopaty 
should be taken into account. Though it appears earlier and does not asociate the ocular 
motility signs characteristic for WE, pancreatic encephalopaty may be considered as 
differential diagnosis in those with severe acute pancreatitis (Sun, Yang et al. 2006; 
Thorarinsson, Olafsson et al. 2011). Variant Creuzefeld-Jakob disease and Fabry’s disease may 
resemble WE. Inflamatory diseases of the brain (infectious, autoimmune or disimmune), 
especially those with perimidline tropism, may present with clinical pictures compatible with 
WE. Among these we emphasize viral encephalitis and meningoencephalitis (influenza  
A, West Nile, Japanes, Murray, citomegalovirus, Herpes simplex), tuberculose 
meningoencephalitis, paraneoplastic cerebelitis, ventriculoencephalitis, acute disseminated 
encephalomyelitis, limbic encephalitis, brainstem encephalitis and primary or secondary 
cerebral vasculitides (Brechtelsbauer, Urbach et al. 1997; Torgovnick, Arsura et al. 2000; 
Chung, Kim et al. 2003; Bertrand, Brandel et al. 2009). Pontine or extrapontine mielinolysis, 
adult onset Leigh disease and other mitochondrial encephalopaties may be included in the 
diferential diagnosis of WE. In certain selected cases, the recently described ‘chronic 
lymphocitic inflamation with pontine perivascular enhancement responsive to steroids’ 
syndrome (CLIPPERS) (Pittock, Debruyne et al. 2010) and ‘cerebellar ataxia, neuropathy and 
vestibular areflexia syndrome’ (CANVAS) (Szmulewicz, Waterston et al. 2011) may also be 
taken into account. The clinical picture of Miller-Fischer syndrome, African seasonal ataxia 
and tropical ataxic polineuropathy may resemble WE. Percheron artery thrombosis or 
embolia, basilar artery trombosis and deep cerebral veins thrombosis may also be included 
in the differential diagnosis of WE. Thalamic and mamillothalamic tract infarcts occuring in 
individuals with previous strategicaly localised lesions may mimic WE (Bogousslavsky, 
Regli et al. 1988; Ghika-Schmid and Bogousslavsky 2000). Brain neoplasy involving the 
perimidline regions (e.g. primary cerebral lymphoma, bilateral thalamic glioma) may 
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sometimes be considered. In children WE may mimik meningitis. Regarding atypical WE 
presentations, the differential diagnosis should be adapted for each situation. Optic neuritis 
should be considered in those presentig with optic nerve inolvement. Leber hereditary optic 
neuropathy precipitated by TH deficiency that also resulted in WE has been reported, and 
should be considered in WE patients with optic nerve involvement unresponsive to TH 
administration (Li and Rucker 2010).  
10. Treatment  
WE is a medical emergency. Its etiopathogenic treatment implies the restoration of adequate 
brain TH levels. As detailed further on, this is optimally accomplished by high dose 
parenteral TH administration. The correction of coexisting hypomagnesaemia (by 
intravenous Mg sulphate administration in doses titrated against Mg serum levels) is 
mandatory. The reinstitution of a balanced diet and the elimination of the associated 
modifiable predisposing factors are also required. Scientific evidences regarding the optimal 
dose, frequency, route and duration of TH administration for WE treatment are currently 
lacking. The management of the WE patients is commonly conducted according to the 
empirical recommendations provided by the local guidelines. Since any delay in TH 
administration may result in permanent neurologic sequelae or death, parenteral TH 
administration should be started as soon as possible. The decision of initiating parenteral 
TH administration should be taken on clinical grounds and should never be delayed until 
the paraclinical workup is completed and/or the results are available (Thomson and 
Marshall 2006; Sechi and Serra 2007; Galvin, Brathen et al. 2010; Thorarinsson, Olafsson et al. 
2011). The identification and treatment of WE comorbidities is mandatory. Supportive and 
symptomatic therapy should be provided. These should be adapted to each patient, and will 
not be detailed in the present chapter. Considering that carbohydrate load may precipitate 
or aggravate WE, glucose should never be administered prior to TH (! hypoglycaemic coma 
or seizures). To the best of our knowledge, scientifically rigorous studies assessing the 
optimal TH posology for the treatment of WE have not been conducted. However, the 
results of several uncontrolled studies on adults are available. It is commonly accepted that 
a rapid restoration of brain TH levels is more beneficial than a slower restoration, therefore 
frequent high dose intravenous administration being required. Low parenteral TH doses 
and the oral route of administration are inefficient for the treatment of WE (Thomson, Cook 
et al. 2002; Galvin, Brathen et al. 2010). It was reported that WE patients treated with 
parenteral TH doses of 50 or 100 mg per day fully recovered in only up to 16% of the cases, 
while death occurred in up to 20% (Victor 1989; Thomson, Cook et al. 2002). The 
recommended TH doses range from 100 to 1500 mg per day (Thomson, Cook et al. 2002; 
Sechi and Serra 2007). Within this range, the administration of higher rather than lower TH 
doses is favoured. The therapeutic scheme should be constantly adapted to the patient’s 
evolution according to the best clinical judgement of the treating physician. Differences in 
the therapeutic response of alcoholics and non alcoholics have been reported, alcoholics 
requiring higher doses and for extended periods of time, some advising 500 mg thrice a day 
as the minimum dose. Non alcoholics with WE may have adequate therapeutic response 
providing only 100 to 200 mg of parenteral TH are supplied. According to the 2010 EFNS 
recommendations both alcoholics and non alcoholics should receive a minimum of 200 mg 
thrice a day. In hyperemesis gravidarium related WE cases, patients requiring significantly 






2010). To the best of our knowledge, the pediatric parenteral TH doses have not been 
established. According to the current literature the TH deficient infants were treated with 50 
mg of intramuscular TH hydrochloride for 14 days (Fattal-Valevski, Kesler et al. 2005). The 
opinions regarding the adequate treatment duration vary from a few days of intravenous 
high dose TH (followed by another few days of intramuscular lower doses) to the 
continuation of high dose intravenous TH administration until there is no further clinical 
improvement. The latter appears to be the most reasonable and is recommended by the 
2010 EFNS guideline. Secondary prophylaxis with oral TH (30 mg twice a day) is 
advocated by some. Some suggest that in the absence of clinical improvement TH 
administration should be stopped after 2 or 3 days. Since certain patients may require 
prolonged treatment with doses above 500 mg thrice a day, the decision to stop TH 
treatment in those that seem not to respond should be taken with caution (Sechi and Serra 
2007; Paparrigopoulos, Tzavellas et al. 2010). Concomitant parenteral administration of 
other vitamins, especially of B complex and ascorbic acid, is advocated by some. Niacin 
should be administered whenever signs suggestive of pellagra exist. The available 
pharmaceutical preparates for parenteral administration contain variable quantities of TH 
hydrochloride alone or in combination with other vitamins, especially B complex. 
Parenteral TH hydrochloride is available for subcutaneous, intramuscular and 
intravenous injections. Lipid-soluble TH analogues preparates are not widely available 
(except for benfotiamine, which does not pass the BBB). Oral TH hydrochloride 
administration has very good tolerability, side effects being extremely rarely reported, 
and overdoses being virtually impossible (Baker and Frank 1976; Wrenn, Murphy et al. 
1989; Kitamori and Itokawa 1993). Intravenous thiamine is not contraindicated in 
pregnant or lactating women. According to the current literature, the only serious and 
potentially life threatening side effects of TH administration are anaphylactic and 
anaphylactoid reactions (Thomson, Cook et al. 2002; Harper 2006). These have been 
reported to occur during or in the few hours following TH administration. They are only 
exceptionally encountered in relation with oral TH administration and most frequently 
encountered in relation with bolus intravenous TH administration (Thomson, Cook et al. 
2002; Galvin, Brathen et al. 2010), but even so, parenteral TH administration has a very 
high safety profile. The global estimated incidence of the serious adverse reactions 
following parenteral administration of multivitamin pharmacological products containing 
TH was reported to be 1 in every 5 million intramuscular injections and 1 in every million 
intravenous injections, therefore lower than that of penicillin or streptokinase. Arguments 
for the existence of TH induced anaphylaxis have been provided in a few case reports, but 
it may be speculated that anaphylaxis occurs less frequently than anaphylactoid reactions. 
Sensitivity skin test prior to TH administration is not necessary. In order to minimise the 
risk of anaphylactoid reactions without minimising the benefits of intravenous 
administration, it is recommended that TH is administered over at least 10 minutes by 
intravenous infusion. Ideally, when administering parenteral TH, rapid access to cardio-
pulmonary resuscitation facilities should be available (Luskin and Luskin 1996; Harper 
2006; Galvin, Brathen et al. 2010). According to the 2010 EFNS guideline TH should be 
given to all patients with suspected or manifest WE, before any carbohydrate, 
intravenously (diluted in 100 ml of normal saline or glucose solution; 30 minutes infusion) 
or intramuscularly, in doses of at least 200 mg thrice a day, even in the absence of 
resuscitation facilities, until there is no further clinical improvement (level C evidence). 
The early restoration of an adequate diet is advised (Galvin, Brathen et al. 2010).  
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11. Red flags for WE, red flags for TH 
In order to prevent irreversible brain damage and death, TH should be administered as soon 
as possible to all WE patients.  However, even when best clinical management is provided, 
the diagnosis of WE may be overlooked. Evidence based recommendations for the 
identification of patients that should receive parenteral TH are not available, but, as 
discussed, criteria for the accurate identification of WE in alcoholics have been proposed in 
1997 by Cain and in 2002 by the UK Royal College of Physicians. Since parenteral TH 
administration is reasonably cheap and safe, overtreatment is preferred, some advising that 
parenteral TH should be routinely administered until neurologic assessments are made and 
paraclinical data are available to all patients prone to TH deficiency presenting in the 
emergencies departments (even in the absence of other reasonable arguments for WE), and 
the 2010 EFNS guideline recommending that a low threshold for parenteral TH 
administration is maintained (Ogershok, Rahman et al. 2002; Thomson and Marshall 2006; 
Galvin, Brathen et al. 2010; Thorarinsson, Olafsson et al. 2011). Red flags for WE and for TH 
administration include prior history of WE, presence of any of the classical triad signs, 
chronic ethanol abuse, acute alcohol intoxication, delirium tremens, altered mental status, 
altered consciousness, hypothermia, hyperthermia, edema, tachycardia, hypotension, 
cardiac failure and lactic acidosis, persistent emesis, impaired nutrition (prolonged fasting, 
malnourishment, eating disorders and other psychiatric disorders, exclusive parenteral 
nutrition, infants fed by nutritionally impaired women, neglected pediatric, geriatric and 
disabled persons), recent significant weight loss, low body mass index (BMI), history of 
gastrointestinal surgery, consumptive diseases (including malignancies –especially digestive 
tract and in children acute leukemia, AIDS, malaria, tuberculosis, meningoencephalitis, 
thyreotoxicosis), chronic liver disease, chronic dialysis, hepatic and uremic encephalopathy, 
pregnancy and lactation (Lana-Peixoto, Dos Santos et al. 1992; Antunez, Estruch et al. 1998; 
Ihara, Ito et al. 1999; Vasconcelos, Silva et al. 1999; Bleggi-Torres, de Medeiros et al. 2000; 
Donnino, Vega et al. 2007; Sechi and Serra 2007). Special consideration regarding parenteral 
TH administration should receive all those on chronic diuretic drugs presenting for cardiac 
failure (Khan and Garg 2011). 
12. Prognosis  
The majority of the WE cases are cured (with or without sequelae) providing prompt and 
adequate treatment is administered. In the absence of adequate therapy, WE has high 
mortality and morbidity, resulting in death in up to 24% of the cases, and in permanent 
disability in 75 to 85% of the survivors (Thomson, Cook et al. 2002; Donnino, Vega et al. 
2007; Thorarinsson, Olafsson et al. 2011). Alcoholics have worst prognosis than non 
alcoholics. Death or persistent sequelae have also been reported to occur in non alcoholic 
patients, especially in those with hyperemesis gravidarium (Sechi and Serra 2007). Those 
with fewer MRI lesion, and with lesions restricted to the periaqueductal grey area and 
thalami seem to have a good prognosis, while those with cortical MRI lesions seem to have a 
worse prognosis (Varnet, De Seze et al. 2002; Zuccoli, Santa Cruz et al. 2009). The most 
serious sequelae are gait disturbances and KS. Gait disturbances were reported to persist in 
61% of the survivors. When present, KS was reported to persist for at least two years in 56 to 






Halliday et al. 1997). In certain cases, KS related to alcohol consumption and TH deficiency 
may appear in the absence of an overt episode of WE or after an interval of time of apparent 
health, probably due to a precipitating factor that alters the equilibrium of a susceptible 
brain (Harper, Giles et al. 1986; Galvin, Brathen et al. 2010). Several authors denominate the 
sequelae of WE ‘chronic WE’, though they not the consequence of persistent TH deficiency 
(Harper, Giles et al. 1986; Kopelman, Thomson et al. 2009; Thorarinsson, Olafsson et al. 
2011). A true chronic form of WE, consequence of the cumulative effects of several mild, 
subclinical, more or less reversible episodes of TH deficiency, might exist, especially in 
alcoholics (Galvin, Brathen et al. 2010). 
13. Prophylaxis  
Currently there are no evidence based recommendations for the primary or secondary 
prophylaxis of WE, but attempts for TH deficiency prophylaxis have been made either by 
fortifying food or alcoholic beverages with TH or by administering oral or parenteral TH 
to selected populations considered at risk. Their efficacy has not been thoroughly 
evaluated in controlled studies. The fortification of food with TH (commonly flour and 
rice, but also margarine, soft drinks and other products) is inexpensive and technically 
feasible. Empirical primary prophylactic approaches are currently implemented in several 
regions. The fortification of food with TH is legally mandatory in certain areas (i.e. 
Australia, UK, Denmark, Canada, Chile) and optional but reglemented by law in others 
(i.e. Switzerland, Brazil, Yemen). Several countries have the minimum content of flour TH 
established by law (WHO 1999). Commonly, TH mononitrate is used for the fortification 
of flower, rice and soft drinks. The supplementation of alcoholic beverages (beer and vine) 
is feasible, and has been proposed as it better targets those that take most of their caloric 
intake from alcoholic beverages. However, experimental data suggests that alcohol 
consumption and/or malnourishment lead to impaired TH and hydro-soluble TH 
analogues absorption and/or utilization, and therefore these prophylactic approaches 
may result in limited benefits. The clinical retrospective studies conducted in Australia 5 
years after the legally imposed bread fortification with TH reported a 39% decrease in the 
incidence of WE and a 15% decrease in the prevalence of WE (acute and chronic cases 
reported as WE, Korsakoff psychosis, WKS) that maintained at similar levels since the first 
years, while the necroptic studies reported a decrease in the prevalence of WE from 2.1% 
to 1.1% (Rolland and Truswell 1998). The oral prophylactic administration of high doses 
of TH hydrochloride was shown not to prevent WE in malnourished obese patients on 
therapeutic fasting and in hunger strikers. In this respect it is recommended that in certain 
selected population the prophylaxis of WE should be made by parenteral TH 
administration. All alcoholics and malnourished individuals admitted to hospitals should 
receive 200 to 250 mg of parenteral TH hydrochloride per day for 3 to 5 days. 200 mg of 
parenteral TH should be administered prior to glucose infusion to all those prone to TH 
deficiency and in comatose and status epilepticus patients. Per os TH supplementation (at 
least 15 mg per day, recommended 30 mg twice a day) is advised for the secondary 
prophylaxis of WE. Patients receiving drugs that may deplete the TH stores or 
undergoing dialysis should also receive per os TH supplementation.(Thomson, Cook et al. 
2002; Galvin, Brathen et al. 2010). 
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WE Is a potentially fatal but highly and easily treatable disease occurring throughout the 
world. It is commonly (but not exclusively!) encountered in TH deficient alcoholic and/or 
malnourished susceptible individuals. The topography of the lesions is highly specific, 
commonly the perimidline regions being symmetrically involved. The classical clinical 
hallmark (sometimes completely absent!) consists of ocular motility signs, stance and/or 
gait ataxia and mental status changes having acute or subacute onset. No paraclinical 
investigation can accurately exclude the diagnosis of WE, however, the imagistic and 
laboratory workup is useful for supporting the diagnosis and excluding comorbidities. 
Though the necessity of prompt parenteral TH administration in all WE patients is 
unanimously accepted, evidence based recommendations for its therapeutic management 
are not available. The administration of high dose parenteral TH (recommended at least 200 
mg thrice a day; NB! correction of hypomagnesaemia) should be initiated as soon as 
possible in all patients with suspected WE. Considering the deleterious medical and 
economical consequences of untreated WE, and that parenteral TH is reasonably safe and 
cheap and has no contraindication except prior allergic reaction, high dose parenteral TH 
should be administered to all those presenting to the emergency departments with TH 
deficiency predisposing factors, ethanol intoxication or delirium tremens. The maintenance 
of a high index of suspicion for WE and a low threshold for parenteral TH administration is 
advocated (Thomson, Cook et al. 2002; Sechi and Serra 2007; Galvin, Brathen et al. 2010). 
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